DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for inborn glycerol kinase deficiency — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleInborn glycerol kinase deficiency maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for inborn glycerol kinase deficiency is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Two children with isolated glycerol kinase deficiency were followed for roughly 20 years. Fibroblast glycerol kinase activity was below 10% of reference. One had a deletion of exon 17, the other a mutation in exon 7 (601 A→G); both mothers were heterozygotes. Two maternal male cousins in one family were hemizygotes but had no symptoms. In childhood, the patients showed pronounced sensitivity to fasting and physical exercise. At ages 23 and 31, the same tests were essentially normal except for pronounced ketonaemia. After puberty, the boys had no hypoglycaemic symptoms and reported no problems with their condition. The authors concluded that glycerol is more important as a gluconeogenetic substrate in children than in adults, and that with frequent meals, access to glucose, and avoidance of strenuous sports, the prognosis for a normal adult life is good.
A separate report describes two brothers with glycerol kinase deficiency. The older brother had serious clinical symptoms: mental and growth retardation, abnormal skeleton, spontaneous fractures, and premature loss of abnormal teeth. He and his mother had low serum phosphate. He had elevated serum and urine glycerol, and GKD was found in cultured fibroblasts. Prenatal diagnosis was performed in the second pregnancy. A chorionic villus sample showed normal glycerol kinase activity, but after birth the boy had elevated serum and urine glycerol. Enzymatic analysis in cultured fibroblasts confirmed GKD, despite no expression of the disease. Chromosomal analyses in the parents and both boys were normal. Major rearrangements or deletions were not detected in molecular studies; the hybridisation pattern was normal and no allelic loss was observed.
A third case describes a six-year-old male with the infantile type of glycerol kinase deficiency. He had proximal dominant muscle atrophy and weakness, addisonian pigmentation, and mental retardation. Laboratory findings showed muscular dystrophy, adrenal insufficiency, and glycerol kinase deficiency. He had a small deletion in band Xp21 of the X chromosome.
What is still missing is a clear understanding of why some hemizygotes remain asymptomatic while others have severe symptoms, even within the same family. No reliable prenatal or early biomarker distinguishes the two outcomes. The natural history data are limited to a handful of case reports, and no systematic longitudinal study with standardised metabolic challenge protocols exists. Funding for a multi-centre registry and for genotype–phenotype correlation studies would be needed to move beyond anecdote.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Acta Paediatrica · 2004 · 26 citations
Glycerol kinase deficiency: follow‐up during 20 years, genetics, biochemistry and prognosis
AbstractAIM: To follow two children with isolated glycerol kinase deficiency (GKD) with severe symptoms into adulthood. METHODS: The patients were followed during approximately 20 y and interviewed about symptoms, diet and physical activity. Fasting provocations, bicycle ergometer tests, dietary registrations, enzyme and mutation analysis were performed by standard protocols. RESULTS: The activity of glycerol kinase (GK) in fibroblasts was <10% of reference. One case had a deletion of exon 17, the other a mutation in exon 7 of the GK gene (601 A-->G). Both mothers were heterozygotes. Two maternal male cousins in one of the families were hemizygotes without symptoms. Tests performed in childhood documented pronounced sensitivity to fasting and physical exercise, whereas such tests at 23 and 31 y of age were essentially normal but with pronounced ketonaemia. After puberty, the boys had no hypoglycaemic symptoms and now report no problems with their condition; thus, their phenotype has changed over time. CONCLUSION: The greater importance of glycerol as a gluconeogenetic substrate in children than in adults may explain the episodes in young patients with GKD, often elicited by catabolic stress. With meals at frequent intervals, access to glucose and avoidance of strenuous sports, the prognosis is good for a normal adult life of a young child with isolated GKD and symptoms of hypoglycaemia.
Glycerol kinase deficiency in two brothers with and without clinical manifestations
AbstractWe report two brothers with glycerol kinase deficiency (GKD). The older brother had serious clinical symptoms, mental and growth retardation, abnormal skeleton, spontaneous fractures and premature loss of abnormal teeth. He and his mother had low serum phosphate levels. He had elevated serum and urine glycerol levels and GKD was found in cultured fibroblasts. Prenatal diagnosis was performed in the second pregnancy. Glycerol kinase activity was considered normal in a chorionic villus sample of the foetus. After birth, it was found that the boy had elevated serum and urine glycerol levels. Enzymatic analysis in cultured fibroblasts revealed that this boy also had GKD, in spite of having no expression of the disease. Chromosomal analyses in the parents and both boys were normal. Major rearrangements or deletions were not detected in molecular studies of DNA from the two brothers. The hybridisation pattern was normal and no allelic loss was observed.
A Case With the Infantile Type of Glycerol Kinase Deficiency
AbstractAbstract A male infant with the infantile type of glycerol kinase deficiency is described. At six years of age, he showed proximal dominant muscle atrophy and weakness, addisonian pigmentation and mental retardation. Laboratory investigations revealed muscular dystrophy, adrenal insufficiency and glycerol kinase deficiency. He has a small deletion in a band (Xp21) of the X chromosome. The clinical, biochemical and genetic findings in this patient are reported.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
